Ramelteon: TAK 375.
Article Details
- CitationCopy to clipboard
Authors unspecified
Ramelteon: TAK 375.
Drugs R D. 2005;6(3):186-8.
- PubMed ID
- 15869323 [ View in PubMed]
- Abstract
Ramelteon [TAK 375] is a melatonin (MT1/MT2) receptor agonist that is being developed by Takeda as a treatment for sleep disorders. It is undergoing regulatory review in the US, phase III trials in Europe, and phase II trials in Japan for the treatment of insomnia. Phase II trials are also being conducted in the US for the treatment of circadian rhythm sleep disordersIn September 2004, Takeda submitted an NDA to the US FDA for ramelteon for the treatment of insomnia. In May 2003, data presented at the 156th Annual Meeting of the American Psychiatric Association report that ramelteon is highly selective for the MT1 receptor, and has greater affinity, selectivity and potency than melatonin.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ramelteon Melatonin receptor type 1A Protein Humans YesMultitargetDetails Ramelteon Melatonin receptor type 1B Protein Humans YesMultitargetDetails